Get the Stockscreener App
4.43
4.22%
0.28
Minerva Neurosciences Inc stock is traded at $4.43, with a volume of 94,820.
It is up +4.22% in the last 24 hours and up +12.63% over the past month.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
See More
Previous Close:
$4.15
Open:
$4.07
24h Volume:
94,820
Relative Volume:
0.03
Market Cap:
$187.81M
Revenue:
-
Net Income/Loss:
$-33.65M
P/E Ratio:
-0.9955
EPS:
-4.45
Net Cash Flow:
$-20.83M
1W Performance:
+6.53%
1M Performance:
+12.63%
6M Performance:
+162.12%
1Y Performance:
+83.26%
1-Day Range:
$4.05
$4.44
1-Week Range:
$3.82
$4.44
52-Week Range:
$1.15
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
4.34 | 179.59M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
Minerva Neurosciences Inc (NERV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Minerva Neurosciences (NASDAQ:NERV) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Minerva Neurosciences (NASDAQ:NERV) & UCB (OTCMKTS:UCBJY) Head to Head Analysis - Defense World
Working capital per share of Minerva Neurosciences Inc – MUN:4MNA - TradingView — Track All Markets
Gains Recap: Why Minerva Neurosciences Inc stock is in analyst buy zoneProduct Launch & Free Expert Verified Stock Movement Alerts - moha.gov.vn
MSN Money - MSN
Published on: 2025-12-26 01:20:46 - moha.gov.vn
Reviewing Xenetic Biosciences (NASDAQ:XBIO) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences shareholders approve key governance measures - MSN
Minerva Neurosciences Shareholders Approve Key Governance Measures - TipRanks
Risks Report: Why Minerva Neurosciences Inc. (4MNA) stock stays resilientMarket Activity Summary & Free High Accuracy Swing Entry Alerts - Улправда
Movement Recap: Why analysts upgrade Minerva Neurosciences Inc. stock2025 Growth vs Value & AI Powered Market Entry Ideas - Улправда
How strong is Minerva Neurosciences Inc. stock revenue growthGold Moves & Weekly High Return Forecasts - Улправда
Why analysts upgrade Minerva Neurosciences Inc. stockIndex Update & Risk Controlled Swing Alerts - Улправда
Is Minerva Neurosciences Inc. stock safe for conservative investorsJuly 2025 Fed Impact & Verified Stock Trade Ideas - DonanımHaber
What risks investors should watch in Minerva Neurosciences Inc. stock2025 Earnings Impact & Real-Time Volume Analysis - Улправда
Inderjit Kaul Net Worth (2025) - GuruFocus
Minerva Neurosciences (NERV) Price Target Increased by 12.50% to 4.59 - Nasdaq
Is Minerva Neurosciences Inc. stock a buy for dividend growth2025 EndofYear Setup & Safe Entry Zone Tips - Newser
How risky is Minerva Neurosciences Inc. (4MNA) stock compared to peersPortfolio Performance Report & Long Hold Capital Preservation Plans - Newser
How Minerva Neurosciences Inc. stock reacts to oil prices2025 Top Decliners & Technical Pattern Recognition Alerts - Newser
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Is Minerva Neurosciences Inc. stock attractive for retirement portfolios2025 Earnings Surprises & Capital Efficiency Focused Strategies - Newser
Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst - MSN
Will Minerva Neurosciences Inc. (4MNA) stock boost dividends furtherSell Signal & Fast Exit and Entry Strategy Plans - Newser
Is Minerva Neurosciences Inc. (4MNA) stock cheap vs fundamentalsJuly 2025 Action & Verified Swing Trading Watchlist - Newser
Minerva Neurosciences (NERV) Stock Analysis Report | Financials & Insights - Benzinga
How Minerva Neurosciences Inc. (4MNA) stock compares with tech leadersJuly 2025 Weekly Recap & Stock Portfolio Risk Control - Newser
Market Fear: Why Minerva Neurosciences Inc 4MNA stock stays resilientJuly 2025 Outlook & Capital Efficiency Focused Ideas - moha.gov.vn
How Minerva Neurosciences Inc. stock trades during market volatilityJuly 2025 Catalysts & Free Low Drawdown Momentum Trade Ideas - moha.gov.vn
Performance Recap: What risks investors should watch in Minerva Neurosciences Inc. stock2025 Market Trends & Consistent Return Strategy Ideas - BỘ NỘI VỤ
Contrasting Minerva Neurosciences (NASDAQ:NERV) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Is Transindia Real Estate Limited Undervalued or Overvalued Fair Value ExplainedTechnical Analysis Insights & Zero-Cost Stock Research by Professionals - earlytimes.in
Why Minerva Neurosciences Inc. stock appeals to analysts2025 Major Catalysts & Fast Gain Swing Trade Alerts - newser.com
Why Minerva Neurosciences Inc. (4MNA) stock attracts wealthy investorsPortfolio Growth Summary & High Conviction Buy Zone Picks - newser.com
Using Ichimoku Cloud for Minerva Neurosciences Inc. technicalsMarket Movers & Accurate Buy Signal Notifications - newser.com
Minerva Neurosciences Expands Board Amid Fundraising Effort - The Globe and Mail
Multi asset correlation models including Minerva Neurosciences Inc.July 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
What to do if you’re stuck in Minerva Neurosciences Inc.Trade Signal Summary & Safe Capital Investment Plans - newser.com
Is Minerva Neurosciences Inc. stock vulnerable to regulatory risksForecast Cut & AI Forecast for Swing Trade Picks - newser.com
How buybacks impact Minerva Neurosciences Inc. stock valueEarnings Performance Report & Daily Oversold Stock Bounce Ideas - newser.com
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):